Resp Week 4 Flashcards

1
Q

How much of LC is attributable to smoking?

A

85%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How many smokers get LC?

A

10%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is a passive smoker?

A

An individual who has never smoked but who lives in the same household as someone who does smoke and within the confides of the house

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

How many recognised carcinogens are there in ciggarrettes?

A

60

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the 2 recognised families of ciggarettes?

A

Polycyclic aromatic hydrocarbons and N-nitrosamines

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Describe polycyclic aromatic hydrocarbons

A
  • Unfiltered tobacco products, home rolled cigarettes, older type of cigarettes
  • More likely to give lung cancer development a boost in the central part of the lung in the bronchi
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Describe N-nitrosamines

A
  • New types of cigarette

- more prone to causing adenocarcinomas (Periphery of lung)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Describe how inherited polymorphisms may affect the chances of getting LC

A

We all inherit a differeing risk of developing lung cancer due to how our body reacts to the carcinogens
for example we all have a different susceptibility to nicotine addiction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are the 2 main pathways of carcinogens in the lung?

A

The lung periphery (adenocarcinoma) and the central lung airways (squamous cell carcinoma)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are the 4 main types of LC and what are their prevelence in respect to each other

A
Squamous cell - 40%
Adenocarcinoma - 41%
Small cell carcinoma - 15%
Large cell carcinoma - 4%
[histologically there are 2 types, small cell and non small cell to which the prevalence is 15% and 85% respectively]
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Describe primary LC

A
  • Grows clinically silent for many years, presenting late in its natural history
  • May have few, if any signs or symptoms until the disease is very advanced
  • May be found incidentally during investigation for something unrelated
  • Generally speaking symptomatic LC is fatal
  • Central tumours involving large bronchi are more likely to bleed -> Causes haemoptysis-> take very seriously
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Describe the effects of bronchial obstruction caused as one of the local effects of LC

A
  • Collapse of the lung
  • Leads to the retention of cells and secretions which would normally have been removed by the mucocillary escalator leading to endogenous lipid pneumonia
  • Infection/abcess formation
  • Bronchiectasis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Describe the pleural effects caused as one of the local effects of LC

A
  • Inflammatory

- Malignant invasion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Describe how LC may directly invade the chest wall

A

Phrenic nerve -> diaphragmatic paralysis
L recurrent laryngeal nerve -> hoarse, bovine cough
Brachial plexus -> pancoast T1 damage
Cervical sympathetic -> Horners syndrome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is a pulmonary mass?

A

An opacity in the lung over 3cm with no mediastinal adenopathy or atelectasis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is a pulmonary nodule?

A

An opacity in the lung UP TO 3cm with no mediastinal adenopathy or atelectasis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What are the symptoms of LC

A
Chronic coughing
Coughing up blood
Wheeze
Chest and bone pain
Chest infections
Difficulty swallowing
Raspy, hoarse voice
SOB
Unexplained weight loss
Nail clubbing
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What are the clinical signs of LC

A
chest signs
Clubbing
Lymphadenopathy
Horners syndrome
Pancoast tumour
Superior vena cava obstruction
Heptaomegaly
skin nodules (metastasis)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What are the initial investigations for LC

A
CXR
FBC
Spirometry
Clotting screen
Renal and liver functions 
Calcium levels
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What are some of the more advanced investigations for LC?

A
Bronchoscopy
EBUs
Image guided lung biopsy
Image guided liver biopsy
FNA of neck node of skin metastasis
Excision of cerebral metastasis
Bone biopsy
Mediastinoscopy/otmy
Surgical excision biopsy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Describe the performance status for LC

A
0 = fully active
1 = symptoms but ambulantory
2 = 'up and about' >50%, unable to work
3 = 'up and about' <50%, limited self care
4 = bed or chair bound
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What are the treatment options for LC

A

Surgery
Wedge resection
Lobectomy
Pneumonectomy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What are the 3 types of radiotherapy?

A

Radical - attempting to cure
Pallitative - symptoms, not attempting to cure
Sterotactic - Not attempting to cure, but trying to stop it getting worse

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What are the 3 aspects of TNM staging?

A
  1. How big it is and how far it has spread/size and position of tumour (T)
  2. Whether cancer cells have spread into the lymph nodes (N)
  3. Whether the tumours have spread anywhere else in the body, i.e metastases (M)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Describe a T1 tumour

A
  • Tumour less than or equal to 3cm in greatest dimension, surrounded by lung or visceral pleura without bronchoscopic evidence of involvement of the main bronchus
  • T1a = minimally invasive adenocarcinoma tumour <=1cm in greatest dimension
  • T1b = Tumour <=2cm
  • T1c = Tumour <=3cm
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Describe a T2 Tumour

A

Tumour >3cm but <=5cm or tumour with any of the following features:
- Involves main bronchus
- Invades visceral pleura
- Associated with atelactasis or obstructive pneumonitis that extends to the hilar region involving part or all the lung
T2a tumour >3cm but <4cm in greatest dimension
T2b tumour >4cm but <5cm in greatest dimension

27
Q

Describe a T3 tumour

A

Tumour >5cm but <7cm or one that directly invades any of the following:
- Chest wall
- Phrenic nerve
- Parietal pericardium
Or separate tumour nodules in the same lobe as the primary

28
Q

Describe a T4 tumour

A
Tumour >7cm or invades any of the following:
- Diaphragm
- Mediastium
- Heart 
- Great vessels
- Trachea
- Recurrent laryngeal nerve
- Oesophagus
- Vertebral body
- Carina
Separate tumour nodules in a different ipsilateral lobe
29
Q

Describe the N staging of a tumour

A

N0- no regional lymph node metastases
N1- ipsilateral peribronchial, hilar or intrapulmonary nodes including by direct extension
N2- ipsilateral mediastinal, subcarinal
N3- Contralateral mediastinal, contralateral hilar, scalene or supraclavicular

30
Q

Describe the M staging of a tumour

A
M0 - no distant metastesis 
M1- distant metastesis
M1a - separate tumour nodules in a contralateral lobe
M1b - single distant metastasis
M1c - multiple distant metastasis
31
Q

What are 4 common sites of metastesis?

A

Cerebral
Skeletal
Adrenal
Liver

32
Q

How many LC patients are operable?

A

10%

33
Q

How many of those who go through surgery are cured from cancer?

A

1/2

34
Q

Would you operate for a pleural effusion?

A

No

35
Q

Would you operate when there is chest wall invasion in lc

A

Yes- is possible to resect invaded ribs and soft tissues and reconstruct chest wall

36
Q

Would you operate in phrenic nerve palsy caused by LC

A

No, extensive invasion of the mediastinum is inoperable

37
Q

Would you operate for a collapsed lobe or lung

A

You could but you would need to be careful about the extent of the tumour

38
Q

What are you looking for in blood tests for a LC pateint being considered for surgery

A

anaemia
abnormal LFTs
Abnormal bone profile

39
Q

What are some common reasons for perioperative death?

A
ARDS
Bronchopneumonia
PTE
Pneumonthroax
Intra-thoracic bleeding
40
Q

What are some common non fatal complications of surgery

A
Post thoracotomy wound pain
Empyema
BPF
Wound infection
AF
MI
Post of resp insufficiency
Gastroparesis/Constapation
41
Q

Give the operative mortality for the following procedures:

  • Pneumonectomy
  • Wedge resection
  • Lobectomy
  • Open/Close thoracotomy
A
  • Pneumonectomy: 5-10%
  • Wedge resection: 3-5%
  • Lobectomy: 2-3%
  • Open/Close thoracotomy: 5%
42
Q

What is the doubling time of NSCLC

A

129days

43
Q

How many nsclc cases are operable

A

Max 25%

44
Q

What is the FEV1 needed for a lobectomy

A

> 1

45
Q

What is the FEV1 needed for a pneumonectomy

A

> 2

46
Q

Describe adjuvant therapy in LC treatment

A

= Post op

  • Chemotherapy -> to increase chance of cure/reduces risk of reccurence
  • Adjuvant Rt detrimental in stage I and II; possible benefit if mediastinal nodes or involved in margins
47
Q

Describe neoadjuvant therapy in LC treatment

A

= Pre op

  • Not used in clinical practice
  • Stage III: Preoperative chemotherapy demonstrates some advantages, non in stage I or II
48
Q

Describe the variety of regimes in radical rt

A

55Gy in 20 fractions: treated daily monay - friday for 4 weeks
54Gy in 36 fractions: treated three times daily for 12 consecutive days

49
Q

Describe the Acute side effects of radical rt

A

Lethargy
Oesophagitis
SOB due to pneuomonitis

50
Q

Describe the long term side effects of radical rt

A

Pul fibrosis

51
Q

what is the benefit of concurrent chemoRT

A

4-5% overall survival benifit at 5 years

52
Q

What are the palliative treatment options for NSCLC

A
Immunotherapy
TKI
Palliative rT
Combiniation of the above
Chemotherapy
53
Q

Describe palliative chemotherapy in NSCLC

A
  • Given as a doublet regime: two drugs given as IV infusion every 3 weeks
  • Most centres give 4 cycles
  • Improves survival by further 3-5 months
54
Q

Describe palliative immunotherapy in NSCLC

A
  • New treatment modality
  • PDL1 (programmed death ligand) - protein that prevents immune system attacking cells in the body
  • Cancer good at masking themselves from immune system via PDL1 expression (immunotherapy works by upregulating immune system and ‘unmasking’ cancers)
  • Can be used first line if PDL1 Score > 50%, otherwise can be used second line
55
Q

What is the doubling time for patients with SCLC

A

29 days

56
Q

What are the different types of pleural effusion?

A

Transudate: non-inflammatory
Exudate: Inflammatory

57
Q

Describe lights criteria

A

=Criteria for determining if exudate

  • Protein: Pleural fluid/serum ratio >0.5
  • LDH: pleural fluid/serum fluid ration >0/6
  • Effusion LDH level greater than two-thirds the upper limit of the laboratory’s reference range of serum LDH.
58
Q

What are the common causes of transudates

A

LV failure

Liver cirrhosis

59
Q

What are the common causes of exudate

A

Malignancy
Parapneumonic effusions: empyema
TB

60
Q

What is the investigations for a pleural effusion?

A

Ultrasound: more sensitive than CXR
CXR
CT thorax

61
Q

Describe the management of a pleural effusion

A
  • pH less than 7.2 with pneumonia, pus or blood = chest drain
  • Transudate, treat the underlying cause, may not need CT imagine
  • Exudate: unless cause identified will need futher investigation- further imaging and/or pleural biopsy
62
Q

What is a pneumothorax?

A

Collection of air within the pleural space

63
Q

What are the different types of pneumothorax?

A
  • Primary spontaneous - happens with normal lungs
    (Sudden event - weak areas on the lung surface rupture and leak air into the pleural cavity)
  • Secondary spontaneous - same as primary spontaneous pneumothorax except already has pre-existing condition
  • Traumatic - take a guess bud
  • Iatrogenic - Trauma but takes place due to medial procedure
  • Tension - when air is trapped in the pleural space under positive pressure, displacing mediastinal structure and compromising cardiopulmonary function